<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00002812</url>
  </required_header>
  <id_info>
    <org_study_id>1961</org_study_id>
    <secondary_id>CCG-1961</secondary_id>
    <secondary_id>CDR0000064953</secondary_id>
    <nct_id>NCT00002812</nct_id>
  </id_info>
  <brief_title>Combination Chemotherapy in Treating Children With Acute Lymphocytic Leukemia</brief_title>
  <official_title>Treatment of Patients With Acute Lymphoblastic Leukemia With Unfavorable Features: A Phase III Group-wide Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Children's Oncology Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Children's Oncology Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing
      so they stop growing or die. Combining more than one drug and giving the drugs in different
      combinations may kill more cancer cells.

      PURPOSE: Randomized phase III trial to compare the effectiveness of standard combination
      chemotherapy treatment with more intensive combination chemotherapy in treating children with
      acute lymphocytic leukemia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES: I. Compare the outcomes in children with higher risk acute lymphocytic leukemia
      (ALL) treated with postinduction chemotherapy based on marrow response on day 7 of induction
      therapy: for patients with rapid early response (M1/M2), standard vs intensified
      consolidation chemotherapy and standard vs prolonged duration of intensification
      chemotherapy; for patients with slow early response, addition of doxorubicin vs idarubicin
      and cyclophosphamide to intensification chemotherapy. II. Decrease the incidence of avascular
      necrosis by alternating dexamethasone dosing in patients undergoing 2 courses of delayed
      intensification. III. Assess the impact of day 7 marrow status on outcome in these patients.
      IV. Determine prognosis more precisely by supplementing presenting clinical features,
      immunophenotype, ploidy, cytogenetics, and early marrow response with BAX/BCL-2 ratios,
      pattern of tyrosine kinase activation, leukemic burden following induction and
      intensification therapy, and development of high antibody titer to E. coli asparaginase. V.
      Correlate the traditional prognostic factors of day 7 marrow response, immunophenotype,
      ploidy, cytogenetics, and early marrow response with BAX/BCL-2 ratios.

      OUTLINE: This is a partially randomized, multicenter study. Patients are stratified by
      center. Patients receive one course of the VPLD regimen comprised of vincristine IV and
      daunorubicin IV over 15 minutes to 2 hours on days 0 and 7, oral prednisone daily on days
      0-7, intrathecal cytarabine on day 0, and asparaginase or pegaspargase intramuscularly on
      days 3, 5, and 7. Patients are assigned to 1 of 2 two postinduction chemotherapy groups based
      on bone marrow response on day 7 of induction. Patients with M1/M2 marrow on day 7 are
      considered rapid early responders. Patients with M3 marrow on day 7 are considered slow early
      responders. Group 1: Rapid early responders Patients receive 2 additional courses of VPLD
      induction chemotherapy. Patients are then randomized to 1 of 4 treatment arms: Arm I:
      Beginning on day 35 of induction therapy, patients receive standard Berlin-Frankfurt-Munster
      (BFM) regimen with standard delayed intensification. Standard BFM for patients in arm I
      consists of the following: consolidation over 5 weeks with cyclophosphamide, cytarabine, and
      mercaptopurine; interim maintenance over 8 weeks with oral methotrexate and mercaptopurine
      (MTX/MP); and delayed intensification over 7 weeks consisting of reinduction with
      vincristine, doxorubicin, oral dexamethasone, and asparaginase or pegaspargase followed by
      reconsolidation with cyclophosphamide, thioguanine, and cytarabine. Arm II: Patients receive
      standard BFM regimen with double delayed intensification. Patients receive therapy similar to
      those in arm I, but dexamethasone is interrupted for 1 week during delayed intensification
      and the intensification regimen is repeated, separated by an 8 week interim maintenance
      course of oral MTX/MP. Arm III: Patients receive augmented BFM regimen with standard delayed
      intensification. Patients receive 9 weeks of consolidation therapy with 2 courses of
      vincristine and pegaspargase alternating with the arm I consolidation therapy. Vincristine,
      intravenous methotrexate, and pegaspargase (the Capizzi I regimen) are substituted for oral
      MTX/MP in the interim maintenance regimen. Pegaspargase is substituted for asparaginase and
      two additional doses of vincristine are administered during delayed intensification. Arm IV:
      Patients receive augmented BFM regimen with double delayed intensification. Patients receive
      intensified chemotherapy throughout, combining the additional therapy given to patients in
      arms II and III. Patients receiving augmented BFM regimen receive pegaspargase instead of
      asparaginase. Patients with CNS disease at diagnosis are treated only on arm IV. Patients who
      are Philadelphia chromosome positive and do not have a bone marrow donor are nonrandomly
      assigned to the treatment group for slow early responders. All RER patients receive the same
      maintenance therapy with vincristine/prednisone and oral MTX/MP. Intrathecal methotrexate is
      administered periodically throughout protocol treatment. Group 2: Slow early responders
      Patients receive augmented BFM consolidation therapy and Capizzi I interim maintenance
      identical to that received by rapid early responders in arm IV. Patients are then randomized
      to receive double delayed intensification with either idarubicin or doxorubicin and
      concurrent cyclophosphamide. All patients receive the same maintenance therapy with
      vincristine/prednisone and oral MTX/MP. Intrathecal MTX is administered periodically
      throughout protocol treatment. Patients with CNS disease at entry receive craniospinal
      irradiation daily for 5 consecutive days beginning on day 0 of consolidation therapy. All
      slow early responders at diagnosis receive cranial irradiation daily for 5 consecutive days
      during consolidation therapy. Patients with testicular leukemia at diagnosis receive
      bilateral testicular irradiation daily for 5 consecutive days during consolidation
      chemotherapy. Groups 1 and 2: Maintenance therapy continues for 2 years for girls or 3 years
      for boys beyond completion of consolidation therapy. Patients are followed every 4-6 weeks
      for 1 year, every 3 months for 1 year, every 6 months for 2 years, and then annually
      thereafter.

      PROJECTED ACCRUAL: Approximately 1,520 patients will be accrued for this study over 4 years.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 1996</start_date>
  <primary_completion_date type="Actual">March 2006</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Event Free Survival</measure>
    <time_frame>from the time of randomization where the life table events will consist of the first occurrence of the following events: failure to achieve remission, leukemic relapse at any site, death, or occurrence of a second malignancy.</time_frame>
    <description>The primary outcome index used in examining most of the randomized treatment groups will be event-free survival (EFS).</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">2078</enrollment>
  <condition>Leukemia</condition>
  <arm_group>
    <arm_group_label>Arm A - Standard BFM of Standard Duration (RER)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Induction chemotherapy Days 0 - 7. Prednisone 60 mg/m² PO 4 x day. Vincristine sulfate 1.5 mg/m² IV push weekly x 2 Days 0 and 7. Daunomycin (daunorubicin hydrochloride) 25 mg/m² IV push (over 15 min.) weekly x 2 Days 0 and 7. IT Cytosine Arabinoside (cytarabine, Ara-C) Day 0. Asparaginase 6000 IU/m² IM x 3 Days 3, 5, and 7. Day 7 Bone Marrow. Consolidation (Phase II) (5 weeks) Prednisone Taper, cyclophosphamide, cytosine arabinoside (Ara-C), mercaptopurine, vincristine sulfate, pegaspargase, IT Methotrexate and radiation therapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B - Standard BFM with Double Delayed Intensification (RER)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Induction chemotherapy Days 0 - 7. Prednisone 60 mg/m² PO 4 x day. Vincristine sulfate 1.5 mg/m² IV push weekly x 2 Days 0 and 7. Daunomycin (daunorubicin hydrochloride) 25 mg/m² IV push (over 15 min.) weekly x 2 Days 0 and 7. IT Cytosine Arabinoside (cytarabine, Ara-C) Day 0. Asparaginase 6000 IU/m² IM x 3 Days 3, 5, and 7. Day 7 Bone Marrow Consolidation (5 weeks) (Phase II) Prednisone Taper, cyclophosphamide, cytosine arabinoside (Ara-C), mercaptopurine, vincristine sulfate, pegaspargase, IT Methotrexate and radiation therapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm C - Augumented BFM of Standard Duration (RER)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Induction chemotherapy Days 0 - 7. Prednisone 60 mg/m² PO 4 x day. Vincristine sulfate 1.5 mg/m² IV push weekly x 2 Days 0 and 7. Daunomycin (daunorubicin hydrochloride) 25 mg/m² IV push (over 15 min.) weekly x 2 Days 0 and 7. IT Cytosine Arabinoside (cytarabine, Ara-C) Day 0. Asparaginase 6000 IU/m² IM x 3 Days 3, 5, and 7. Day 7 Bone Marrow Consolidation (9 weeks) (Phase II) Prednisone Taper, cyclophosphamide, cytosine arabinoside (Ara-C), mercaptopurine, vincristine sulfate, pegaspargase, IT Methotrexate and radiation therapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm D - Augmented BFM with Dbl Delayed Intensification (RER)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Induction chemotherapy Days 0 - 7. Prednisone 60 mg/m² PO 4 x day. Vincristine sulfate 1.5 mg/m² IV push weekly x 2 Days 0 and 7. Daunomycin (daunorubicin hydrochloride) 25 mg/m² IV push (over 15 min.) weekly x 2 Days 0 and 7. IT Cytosine Arabinoside (cytarabine, Ara-C) Day 0. Asparaginase 6000 IU/m² IM x 3 Days 3, 5, and 7. Day 7 Bone Marrow Consolidation (9 weeks) (Phase II) Prednisone Taper, cyclophosphamide, cytosine arabinoside (Ara-C), mercaptopurine, vincristine sulfate, pegaspargase, IT Methotrexate and radiation therapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>asparaginase</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm A - Standard BFM of Standard Duration (RER)</arm_group_label>
    <arm_group_label>Arm B - Standard BFM with Double Delayed Intensification (RER)</arm_group_label>
    <arm_group_label>Arm C - Augumented BFM of Standard Duration (RER)</arm_group_label>
    <arm_group_label>Arm D - Augmented BFM with Dbl Delayed Intensification (RER)</arm_group_label>
    <other_name>E. coli</other_name>
    <other_name>Elspar</other_name>
    <other_name>NSC-109229</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm A - Standard BFM of Standard Duration (RER)</arm_group_label>
    <arm_group_label>Arm B - Standard BFM with Double Delayed Intensification (RER)</arm_group_label>
    <arm_group_label>Arm C - Augumented BFM of Standard Duration (RER)</arm_group_label>
    <arm_group_label>Arm D - Augmented BFM with Dbl Delayed Intensification (RER)</arm_group_label>
    <other_name>Cytoxan</other_name>
    <other_name>NSC-26271</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cytarabine</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm A - Standard BFM of Standard Duration (RER)</arm_group_label>
    <arm_group_label>Arm B - Standard BFM with Double Delayed Intensification (RER)</arm_group_label>
    <arm_group_label>Arm C - Augumented BFM of Standard Duration (RER)</arm_group_label>
    <arm_group_label>Arm D - Augmented BFM with Dbl Delayed Intensification (RER)</arm_group_label>
    <other_name>Cytosine Arabinoside</other_name>
    <other_name>Ara-C</other_name>
    <other_name>Cytosar-U</other_name>
    <other_name>NSC-63878</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>daunorubicin hydrochloride</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm A - Standard BFM of Standard Duration (RER)</arm_group_label>
    <arm_group_label>Arm B - Standard BFM with Double Delayed Intensification (RER)</arm_group_label>
    <arm_group_label>Arm C - Augumented BFM of Standard Duration (RER)</arm_group_label>
    <arm_group_label>Arm D - Augmented BFM with Dbl Delayed Intensification (RER)</arm_group_label>
    <other_name>Daunomycin Hydrochloride</other_name>
    <other_name>Cerrubidine</other_name>
    <other_name>NSC-82151</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dexamethasone</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm A - Standard BFM of Standard Duration (RER)</arm_group_label>
    <arm_group_label>Arm B - Standard BFM with Double Delayed Intensification (RER)</arm_group_label>
    <arm_group_label>Arm C - Augumented BFM of Standard Duration (RER)</arm_group_label>
    <arm_group_label>Arm D - Augmented BFM with Dbl Delayed Intensification (RER)</arm_group_label>
    <other_name>Decadron</other_name>
    <other_name>NSC-34521</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>doxorubicin hydrochloride</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm A - Standard BFM of Standard Duration (RER)</arm_group_label>
    <arm_group_label>Arm B - Standard BFM with Double Delayed Intensification (RER)</arm_group_label>
    <arm_group_label>Arm C - Augumented BFM of Standard Duration (RER)</arm_group_label>
    <arm_group_label>Arm D - Augmented BFM with Dbl Delayed Intensification (RER)</arm_group_label>
    <other_name>Adriamycin</other_name>
    <other_name>NSC-123127</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>idarubicin</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm A - Standard BFM of Standard Duration (RER)</arm_group_label>
    <arm_group_label>Arm B - Standard BFM with Double Delayed Intensification (RER)</arm_group_label>
    <arm_group_label>Arm C - Augumented BFM of Standard Duration (RER)</arm_group_label>
    <arm_group_label>Arm D - Augmented BFM with Dbl Delayed Intensification (RER)</arm_group_label>
    <other_name>Idarubicin Hydrochloride</other_name>
    <other_name>Idamycin</other_name>
    <other_name>NSC-256439</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>mercaptopurine</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm A - Standard BFM of Standard Duration (RER)</arm_group_label>
    <arm_group_label>Arm B - Standard BFM with Double Delayed Intensification (RER)</arm_group_label>
    <arm_group_label>Arm C - Augumented BFM of Standard Duration (RER)</arm_group_label>
    <arm_group_label>Arm D - Augmented BFM with Dbl Delayed Intensification (RER)</arm_group_label>
    <other_name>6-MP</other_name>
    <other_name>Purinethol</other_name>
    <other_name>NSC-755</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>methotrexate</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Arm A - Standard BFM of Standard Duration (RER)</arm_group_label>
    <arm_group_label>Arm B - Standard BFM with Double Delayed Intensification (RER)</arm_group_label>
    <arm_group_label>Arm C - Augumented BFM of Standard Duration (RER)</arm_group_label>
    <arm_group_label>Arm D - Augmented BFM with Dbl Delayed Intensification (RER)</arm_group_label>
    <other_name>NSC-740</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pegaspargase</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm A - Standard BFM of Standard Duration (RER)</arm_group_label>
    <arm_group_label>Arm B - Standard BFM with Double Delayed Intensification (RER)</arm_group_label>
    <arm_group_label>Arm C - Augumented BFM of Standard Duration (RER)</arm_group_label>
    <arm_group_label>Arm D - Augmented BFM with Dbl Delayed Intensification (RER)</arm_group_label>
    <other_name>Asparaginase</other_name>
    <other_name>Oncaspar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>prednisone</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Arm A - Standard BFM of Standard Duration (RER)</arm_group_label>
    <arm_group_label>Arm B - Standard BFM with Double Delayed Intensification (RER)</arm_group_label>
    <arm_group_label>Arm C - Augumented BFM of Standard Duration (RER)</arm_group_label>
    <arm_group_label>Arm D - Augmented BFM with Dbl Delayed Intensification (RER)</arm_group_label>
    <other_name>NSC-10023</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>thioguanine</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm A - Standard BFM of Standard Duration (RER)</arm_group_label>
    <arm_group_label>Arm B - Standard BFM with Double Delayed Intensification (RER)</arm_group_label>
    <arm_group_label>Arm C - Augumented BFM of Standard Duration (RER)</arm_group_label>
    <arm_group_label>Arm D - Augmented BFM with Dbl Delayed Intensification (RER)</arm_group_label>
    <other_name>6-TG</other_name>
    <other_name>NSC-752</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vincristine sulfate</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm A - Standard BFM of Standard Duration (RER)</arm_group_label>
    <arm_group_label>Arm B - Standard BFM with Double Delayed Intensification (RER)</arm_group_label>
    <arm_group_label>Arm C - Augumented BFM of Standard Duration (RER)</arm_group_label>
    <arm_group_label>Arm D - Augmented BFM with Dbl Delayed Intensification (RER)</arm_group_label>
    <other_name>Oncovin</other_name>
    <other_name>NSC-67574</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiation therapy</intervention_name>
    <arm_group_label>Arm A - Standard BFM of Standard Duration (RER)</arm_group_label>
    <arm_group_label>Arm B - Standard BFM with Double Delayed Intensification (RER)</arm_group_label>
    <arm_group_label>Arm C - Augumented BFM of Standard Duration (RER)</arm_group_label>
    <arm_group_label>Arm D - Augmented BFM with Dbl Delayed Intensification (RER)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS: Acute lymphocytic leukemia (ALL) with M3 bone marrow No FAB L3
        morphology CNS or overt testicular leukemia at diagnosis allowed High risk status 10-21
        years old with any white blood count (WBC) 1-9 years old with WBC of 50,000/mm3 or greater

        PATIENT CHARACTERISTICS: Age: 1 to 21 Performance status: Not specified Life expectancy:
        Not specified Hematopoietic: See Disease Characteristics Hepatic: Not specified Renal: Not
        specified

        PRIOR CONCURRENT THERAPY: No prior therapy for ALL except: Emergency therapy for blast
        crisis, superior vena cava syndrome, or renal failure due to leukemic infiltration Biologic
        therapy: Not specified Chemotherapy: Intrathecal cytarabine or methotrexate allowed at
        diagnostic lumbar puncture Induction therapy must begin within 72 hours after intrathecal
        injection Endocrine therapy: At least 1-2 months since prior prednisone, for less than 48
        hours, for reactive airway disease Inhalational steroids allowed Radiotherapy: Not
        specified Surgery: Not specified
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nita L. Seibel, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Children's Research Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Long Beach Memorial Medical Center</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90027-0700</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jonsson Comprehensive Cancer Center, UCLA</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095-1781</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Orange County</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCSF Cancer Center and Cancer Research Institute</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143-0128</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Denver</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80218</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's National Medical Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010-2970</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Chicago Cancer Research Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637-1470</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana University Cancer Center</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202-5289</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Holden Comprehensive Cancer Center at The University of Iowa</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242-1009</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Michigan Comprehensive Cancer Center</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109-0752</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Minnesota Cancer Center</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Cancer Center</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Mercy Hospital</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Nebraska Medical Center</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68198-3330</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Peter's University Hospital</name>
      <address>
        <city>New Brunswick</city>
        <state>New Jersey</state>
        <zip>08901-1780</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NYU School of Medicine's Kaplan Comprehensive Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan-Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mount Sinai School of Medicine</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Herbert Irving Comprehensive Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lineberger Comprehensive Cancer Center, UNC</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599-7295</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital Medical Center - Cincinnati</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229-3039</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ireland Cancer Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106-5065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Columbus</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43205-2696</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Doernbecher Children's Hospital</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97201-3098</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Pittsburgh</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt-Ingram Cancer Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232-6838</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas - MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030-4009</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital and Regional Medical Center - Seattle</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fred Hutchinson Cancer Research Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109-1024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin Comprehensive Cancer Center</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792-6164</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Princess Margaret Hospital for Children</name>
      <address>
        <city>Perth</city>
        <state>Western Australia</state>
        <zip>6001</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>British Columbia Children's Hospital</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6H 3V4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IWK Health Centre</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B3J 3G9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Nguyen K, Devidas M, Cheng SC, La M, Raetz EA, Carroll WL, Winick NJ, Hunger SP, Gaynon PS, Loh ML; Children's Oncology Group. Factors influencing survival after relapse from acute lymphoblastic leukemia: a Children's Oncology Group study. Leukemia. 2008 Dec;22(12):2142-50. doi: 10.1038/leu.2008.251. Epub 2008 Sep 25.</citation>
    <PMID>18818707</PMID>
  </reference>
  <reference>
    <citation>Butturini AM, Dorey FJ, Lange BJ, Henry DW, Gaynon PS, Fu C, Franklin J, Siegel SE, Seibel NL, Rogers PC, Sather H, Trigg M, Bleyer WA, Carroll WL. Obesity and outcome in pediatric acute lymphoblastic leukemia. J Clin Oncol. 2007 May 20;25(15):2063-9.</citation>
    <PMID>17513811</PMID>
  </reference>
  <reference>
    <citation>Avramis VI, Panosyan EH. Pharmacokinetic/pharmacodynamic relationships of asparaginase formulations: the past, the present and recommendations for the future. Clin Pharmacokinet. 2005;44(4):367-93. Review.</citation>
    <PMID>15828851</PMID>
  </reference>
  <reference>
    <citation>Seibel NL, Asselin BL, Nachman JB, et al.: Treatment of high risk T-cell acute lymphoblastic leukemia (T-ALL): comparison of recent experience of the Children's Cancer Group (CCG) and Pediatric Oncology Group (POG). [Abstract] Blood 104 (11): A-681, 2004.</citation>
  </reference>
  <results_reference>
    <citation>Arce FJ, Seibel N, Gaynon PS, et al.: Pharmacokinetics and pharmacodynamics of asparaginases in antibody-negative pediatric patients with higher risk acute lymphoblastic leukemia (ALL): a report from CCG-1961. [Abstract] J Clin Oncol 24 (Suppl 18): A-9027, 508s, 2006.</citation>
  </results_reference>
  <results_reference>
    <citation>Avramis VI, Ettinger L, Martin-Aragon S, et al.: Anti-asparaginase (ASNase) antibody (Ab) in pediatric patients in high risk ALL study (CCG-1961): correlation of Ab and clinical allergy. [Abstract] Proceedings of the American Society of Clinical Oncology 19: A2319, 2000.</citation>
  </results_reference>
  <results_reference>
    <citation>Avramis VI, Panosyan E, Avramis IA, et al.: Anti-asparaginase (ASNase) antibody (Ab) and ASNase activity in children with higher risk acute lymphoblastic leukemia (HR ALL) (CCG-1961). [Abstract] Proceedings of the American Society of Clinical Oncology 21: A-1592, 2002.</citation>
  </results_reference>
  <results_reference>
    <citation>Bhojwani D, Kang H, Menezes RX, Yang W, Sather H, Moskowitz NP, Min DJ, Potter JW, Harvey R, Hunger SP, Seibel N, Raetz EA, Pieters R, Horstmann MA, Relling MV, den Boer ML, Willman CL, Carroll WL; Children's Oncology Group Study; Dutch Childhood Oncology Group; German Cooperative Study Group for Childhood Acute Lymphoblastic Leukemia. Gene expression signatures predictive of early response and outcome in high-risk childhood acute lymphoblastic leukemia: A Children's Oncology Group Study [corrected]. J Clin Oncol. 2008 Sep 20;26(27):4376-84. doi: 10.1200/JCO.2007.14.4519. Erratum in: J Clin Oncol. 2008 Nov 1;26(31):5142..</citation>
    <PMID>18802149</PMID>
  </results_reference>
  <results_reference>
    <citation>Dhall G, Jones T, Radvinsky D, et al.: Adverse reactions to PEG and Erwinia asparaginase and correlation with anti-asparaginase antibody data and survival in children with acute lymphoblastic leukemia (ALL): A report from the Children's Oncology Group study CCG 1961. [Abstract] Blood 114 (22): A-3077, 2009.</citation>
  </results_reference>
  <results_reference>
    <citation>Dhall G, Robison NJ, Rubin JI, et al.: Incidence of adverse reactions to post-induction asparaginase (ASP) therapy in children and adolescents with high-risk acute lymphoblastic leukemia (ALL): A report from the Children's Oncology Group Study CCG-1961. [Abstract] J Clin Oncol 26 (Suppl 15): A-10021, 2008.</citation>
  </results_reference>
  <results_reference>
    <citation>Freyer DR, Devidas M, La M, Carroll WL, Gaynon PS, Hunger SP, Seibel NL. Postrelapse survival in childhood acute lymphoblastic leukemia is independent of initial treatment intensity: a report from the Children's Oncology Group. Blood. 2011 Mar 17;117(11):3010-5. doi: 10.1182/blood-2010-07-294678. Epub 2010 Dec 30.</citation>
    <PMID>21193696</PMID>
  </results_reference>
  <results_reference>
    <citation>Freyer DR, Seibel NL, La MK, et al.: Survival after relapse in higher risk acute lymphoblastic leukemia (ALL) in children and adolescents is independent of prior treatment intensity: a report from the Children's Oncology Group (COG). [Abstract] Blood 112 (11): A-917, 2008.</citation>
  </results_reference>
  <results_reference>
    <citation>Hastings C, Sather HN, Seibel NL, et al.: Outcomes in children and adolescents with a markedly elevated white blood cell count (&gt;200,000) at diagnosis of high risk acute lymphoblastic leukemia (ALL): a report from the Children's Oncology Group. [Abstract] Blood 108 (11): A-1870, 2006.</citation>
  </results_reference>
  <results_reference>
    <citation>Hastings C, Whitlock JA, La M, et al.: Improved outcome of children with Down syndrome (DS) and high risk acute lymphocytic leukemia (HR-ALL): a report of CCG-1961. [Abstract] Blood 110 (11): A-586, 2007.</citation>
  </results_reference>
  <results_reference>
    <citation>Henze G. Early postinduction intensification therapy is essential in childhood acute lymphoblastic leukemia. Nat Clin Pract Oncol. 2008 Sep;5(9):502-3. doi: 10.1038/ncponc1184. Epub 2008 Jul 22.</citation>
    <PMID>18648353</PMID>
  </results_reference>
  <results_reference>
    <citation>Mattano LA Jr, Devidas M, Nachman JB, Sather HN, Hunger SP, Steinherz PG, Gaynon PS, Seibel NL; Children's Oncology Group. Effect of alternate-week versus continuous dexamethasone scheduling on the risk of osteonecrosis in paediatric patients with acute lymphoblastic leukaemia: results from the CCG-1961 randomised cohort trial. Lancet Oncol. 2012 Sep;13(9):906-15. Epub 2012 Aug 15.</citation>
    <PMID>22901620</PMID>
  </results_reference>
  <results_reference>
    <citation>Nachman JB, La MK, Hunger SP, Heerema NA, Gaynon PS, Hastings C, Mattano LA Jr, Sather H, Devidas M, Freyer DR, Steinherz PG, Seibel NL. Young adults with acute lymphoblastic leukemia have an excellent outcome with chemotherapy alone and benefit from intensive postinduction treatment: a report from the children's oncology group. J Clin Oncol. 2009 Nov 1;27(31):5189-94. doi: 10.1200/JCO.2008.20.8959. Epub 2009 Oct 5.</citation>
    <PMID>19805689</PMID>
  </results_reference>
  <results_reference>
    <citation>Nachman J, Siebel N, Sather H, et al.: Outcome for adolescent and young adults 16-21 years of age (AYA) with acute lymphoblastic leukemia (ALL) treated on the Children' s Cancer Group (CCG) 1961 study. [Abstract] Blood 104 (11): A-683, 2004.</citation>
  </results_reference>
  <results_reference>
    <citation>Panosyan EH, Grigoryan RS, Avramis IA, Seibel NL, Gaynon PS, Siegel SE, Fingert HJ, Avramis VI. Deamination of glutamine is a prerequisite for optimal asparagine deamination by asparaginases in vivo (CCG-1961). Anticancer Res. 2004 Mar-Apr;24(2C):1121-5.</citation>
    <PMID>15154634</PMID>
  </results_reference>
  <results_reference>
    <citation>Panosyan EH, Seibel NL, Grigoryan RS, et al.: Pharmacokinetics and pharmacodynamics of three asparaginases in pediatric patients with higher risk acute lymphoblastic leukemia: a report from CCG-1961. [Abstract] Blood 104 (11): A-2745, 2004.</citation>
  </results_reference>
  <results_reference>
    <citation>Panosyan EH, Seibel NL, Martin-Aragon S, Gaynon PS, Avramis IA, Sather H, Franklin J, Nachman J, Ettinger LJ, La M, Steinherz P, Cohen LJ, Siegel SE, Avramis VI; Children's Cancer Group Study CCG-1961. Asparaginase antibody and asparaginase activity in children with higher-risk acute lymphoblastic leukemia: Children's Cancer Group Study CCG-1961. J Pediatr Hematol Oncol. 2004 Apr;26(4):217-26.</citation>
    <PMID>15087948</PMID>
  </results_reference>
  <results_reference>
    <citation>Seibel NL, Steinherz PG, Sather HN, Nachman JB, Delaat C, Ettinger LJ, Freyer DR, Mattano LA Jr, Hastings CA, Rubin CM, Bertolone K, Franklin JL, Heerema NA, Mitchell TL, Pyesmany AF, La MK, Edens C, Gaynon PS. Early postinduction intensification therapy improves survival for children and adolescents with high-risk acute lymphoblastic leukemia: a report from the Children's Oncology Group. Blood. 2008 Mar 1;111(5):2548-55. Epub 2007 Nov 26.</citation>
    <PMID>18039957</PMID>
  </results_reference>
  <results_reference>
    <citation>Withycombe JS, Post-White JE, Meza JL, Hawks RG, Smith LM, Sacks N, Seibel NL. Weight patterns in children with higher risk ALL: A report from the Children's Oncology Group (COG) for CCG 1961. Pediatr Blood Cancer. 2009 Dec 15;53(7):1249-54. doi: 10.1002/pbc.22237.</citation>
    <PMID>19688832</PMID>
  </results_reference>
  <verification_date>August 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 1, 1999</study_first_submitted>
  <study_first_submitted_qc>November 21, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 24, 2003</study_first_posted>
  <last_update_submitted>August 23, 2013</last_update_submitted>
  <last_update_submitted_qc>August 23, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 26, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>untreated childhood acute lymphoblastic leukemia</keyword>
  <keyword>L1 childhood acute lymphoblastic leukemia</keyword>
  <keyword>L2 childhood acute lymphoblastic leukemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Pegaspargase</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Vincristine</mesh_term>
    <mesh_term>Daunorubicin</mesh_term>
    <mesh_term>Idarubicin</mesh_term>
    <mesh_term>Asparaginase</mesh_term>
    <mesh_term>6-Mercaptopurine</mesh_term>
    <mesh_term>Thioguanine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

